Funding for this research was provided by:
Economic and Social Research Council (ES/L008238/1)
Motor Neurone Disease Association
Amyotrophic Lateral Sclerosis Association (18-LGCA-394)
Medical Research Council (MR/L501529/1; MR/R024804/1)
European Community’s Horizon 2020 Programme (H2020-PHC-2014-two-stage; grant agreement number 633413)
National Institute for Health Research (NIHR) Biomedical Research Centre and Maudsley NHS Foundation Trust, King’s College London
Text and Data Mining valid from 2019-03-18
Received: 14 February 2019
Accepted: 12 March 2019
First Online: 18 March 2019
Ethics approval and consent to participate
: Full ethical approval for this study was obtained from the relevant University Research Ethics Committees. Consent was obtained for autopsy in accordance with the regulations of the Medical Research Council (MRC) Neurodegenerative Disease Brain Bank Network, Institute of Psychiatry, Psychology and Neuroscience, Kings College London, UK.
: Not applicable.
: AAC reports consultancies for Biogen Idec, Mitsubishi-Tanabe Pharma, Cytokinetics Inc., Treeway, Chronos Therapeutics Inc., GSK and OrionPharma in the past 5 years, and was Chief Investigator for clinical trials from Cytokinetics Inc. and OrionPharma. AAC is a collaborator in a Phase 2 clinical trial of Triumeq, an antiretroviral drug, in ALS. None of the other co-authors report any competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.